Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled...

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery
• Pharmacokinetics

Background:

• Current regulatory guidelines for dissolution specifications rely on averaged data, potentially leading to information loss and bias.
• A level A in vitro-in vivo correlation (IVIVC) is often used, with a maximum 20% difference allowed for AUC and Cmax between reference and test formulations.

Purpose of the Study:

• To introduce and evaluate a novel 'individual approach' for establishing dissolution specifications, contrasting it with the 'classical approach' using averaged data.
• To demonstrate the enhanced sensitivity and reliability of the individual approach in detecting formulation differences.

Main Methods:

• Development of scenarios based on in vitro-in vivo dissolution rate coefficients with a level A IVIVC for controlled-release formulations.
• Simulation of 1000 dissolution assays for six additional batches to compare the individual and classical approaches.
• Calculation of Cmax ratios between reference and test formulations to assess sensitivity.

Main Results:

• The individual approach demonstrated higher sensitivity in detecting differences between reference and batch formulations compared to the classical approach.
• Simulations showed the individual approach is more effective in identifying potential in vivo performance variations.
• The new methodology provides wider dissolution specification limits, ensuring better control over in vivo variability.

Conclusions:

• The individual approach offers a more robust and sensitive method for establishing dissolution specifications than the classical averaged data approach.
• This methodology enhances the assurance of consistent in vivo performance for drug products by considering individual variabilities.
• Implementing the individual approach can lead to improved drug product quality and regulatory compliance.